Document:

Securities Purchase Agreement

 Exhibit 10.1 
 SECURITIES PURCHASE AGREEMENT 
 This Securities Purchase Agreement (this
“Agreement”) is dated as of December 20, 2010, by and among Cambridge Heart, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature pages hereto (each,
including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). 
 WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(2) of the Securities Act (as defined below) and Rule 506 promulgated thereunder, the Company desires
to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the
receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agrees as follows: 
 ARTICLE I.

 DEFINITIONS 
 1.1 Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings indicated in this Section 1.1:

 “8-K Filing” shall have the meaning ascribed to such term in Section 4.4.

 “Action” shall have the meaning ascribed to such term in Section 3.1(j).

 “Affiliate” means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Purchaser, any investment fund or managed account that is
managed on a discretionary basis by the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 
 “Bloomberg” means Bloomberg L.P. or, if Bloomberg L.P. no longer reports the applicable pricing or other information, such other data service as may in the future replace Bloomberg
L.P. as the primary industry source of stock market data. 
 “Board of Directors” means
the board of directors of the Company. 
 “Business Day” means any day except Saturday,
Sunday and any day which is a federal legal holiday in the United States or a day on which banking institutions in New York City are authorized or required by law or other governmental action to close. 

“Closing” means the closing of the purchase and sale of Securities pursuant to
Section 2.1. 
 “Closing Date” means the Trading Day on which all of the
Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchaser’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver
the Securities, in each case, have been satisfied or waived. 

  
 1 

 “Common Stock” means the common stock of the
Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed into. 
 “Common Stock Equivalents” means any securities of the Company that entitle the holder thereof to acquire Common Stock at any time, including, without limitation, any debt,
preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 

“Company Counsel” means Nutter, McClennen & Fish LLP with offices in Boston,
Massachusetts. 
 “Disclosure Schedules” shall have the meaning ascribed to such term in
Section 3.1. 
 “Effective Date” means the earlier of (a) the date that
all of the Registrable Securities (as defined in the Registration Rights Agreement) have been registered for resale by the holders thereof pursuant to a registration statement(s) declared effective by the SEC and (b) the date that all of the
Registrable Securities have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume or
manner-of-sale restrictions. 
 “Equitable Exceptions” shall have the meaning ascribed to
such term in Section 3.1(c). 
 “Escrow Agent” means Iberiabank, a Louisiana
State banking corporation. 
 “Escrow Agreement” means the Escrow Agreement, dated the
date hereof among the Company and the Escrow Agent, in the form of Exhibit A attached hereto. 

“Evaluation Date” shall have the meaning ascribed to such term in Section 3.1(r).

 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder. 
 “Exercise Date” means the
earlier of (a) the date that all of the Registrable Securities (as defined in the Registration Rights Agreement) have been registered for resale by the holders thereof pursuant to a registration statement(s) declared effective by the SEC and
(b) the date that all of the Shares and the Warrant Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 (assuming cashless exercise thereof) without volume or manner-of-sale restrictions. Notwithstanding anything
herein to the contrary, in the event that the Exercise Date has not occurred within the first (1st) year following the date hereof and at any time thereafter the Company or a Purchaser delivers an opinion of counsel reasonably satisfactory to the Company that the Shares and the Warrant Shares
(upon cashless exercise) may be resold pursuant to Section 4(1) under the Securities Act without volume or manner-of-sale restrictions, the Company shall promptly provide all Purchasers with written notice of its receipt of the satisfactory
opinion and the date of such notice shall be deemed the Exercise Date. 

  
 2 

 “Force Majeure” shall mean any unusual event arising
from causes reasonably beyond the control of the Company that could not be reasonably anticipated that causes a delay in or prevents the performance of any obligation under this Agreement or the agreements contemplated hereby, including but not
limited to: acts of God; fire; war; terrorism; insurrection; civil disturbance; explosion; adverse weather conditions that could not be reasonably anticipated; unusual delay in transportation; strikes or other labor disputes; restraint by court
order, order of public authority or failure of the Purchaser’s broker to take action necessary in order for the Company to deliver the Shares electronically through the Depository Trust Corporation (if so requested by the Purchaser) but
specifically not including any event resulting from the failure of the Company’s transfer agent to act or perform any function. 
 “GAAP” shall have the meaning ascribed to such term in Section 3.1(h). 
 “GT” means the law offices of Greenberg Traurig, P.A. located at 5100 Town Center Circle, Suite 400, Boca Raton, FL 33486. 

“Indebtedness” shall have the meaning ascribed to such term in Section 3.1(aa).

 “Initial Press Release” shall have the meaning ascribed to such term in
Section 4.4. 
 “Intellectual Property Rights” shall have the meaning
ascribed to such term in Section 3.1(o). 
 “Legend Removal Date” shall have
the meaning ascribed to such term in Section 4.1(d). 
 “Liens” means a lien,
charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. 

“Lock-Up Agreement” means the Lock-Up Agreement, dated as of the date hereof, to be executed and
delivered to the Company by each of the directors and officers of the Company, in the form of Exhibit B attached hereto. 
 “Material Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b). 

“Material Permits” shall have the meaning ascribed to such term in Section 3.1(m).

 “Offering” shall have the meaning ascribed to such term in Section 2.1.

 “Per-Unit Purchase Price” means $0.20. 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated
association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 
 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding, such as a deposition), whether
commenced or threatened. 
 “Purchaser Party” shall have the meaning ascribed to such
term in Section 4.8. 
 “Purchaser’s Shares” means that number of Shares
of Common Stock equal to such Purchaser’s Subscription Amount divided by the Per Unit Purchase Price as specified adjacent to such Purchaser’s name and beneath the heading “Purchaser’s Shares” on Schedule I attached
hereto. 

  
 3 

 “Registration Rights Agreement” means that certain
Registration Rights Agreement dated of even date herewith, by and among the Company and the Purchasers who are parties thereto. 
 “Registration Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale by the Purchasers of the
Shares and the Warrant Shares. 
 “Restricted Period” shall have the meaning ascribed to
such term in Section 4.11(a). 
 “Rule 144” means Rule 144 promulgated by the
SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule. 

“SEC” means the United States Securities and Exchange Commission. 

“SEC Reports” shall have the meaning ascribed to such term in Section 3.1(h).

 “Securities” means the Shares, the Warrants and the Warrant Shares. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 “Selling Agent” means Dawson James Securities, Inc.

 “Selling Agent Warrants” means a five (5) year warrant to purchase such number of
shares of our Common Stock equal to 8% percent of the aggregate number of Shares issued in the Offering at an exercise price equal to the Warrant Exercise Price and exercisable at the election of the Selling Agent on a cashless basis. 

“Shares” means the shares of Common Stock underlying the Units issued or issuable to
each Purchaser pursuant to this Agreement. 
 “Short Sales” means all “short
sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock). 

“Subscription Amount” means, as to each Purchaser, the aggregate purchase price of
the Units to be purchased by such Purchaser pursuant to this Agreement, as specified adjacent to such Purchaser’s name and beneath the heading “Subscription Amount” on Schedule I attached hereto, in United States Dollars and in
immediately available funds. 
 “Subsequent Financing” shall have the meaning ascribed to
such term in Section 4.11(a). 
 “Subsidiaries” means any subsidiaries of the
Company as defined in Rule 1-02 of Regulation S-X promulgated by the SEC pursuant to the Exchange Act. 

“Supermajority Purchasers” means the Purchasers which, at any given time, hold greater than
66-2/3% of the voting power of the outstanding Shares that have not been resold pursuant to an effective registration statement under the Securities Act or Rule 144 of the Securities Act, provided that at least 20% of such Shares remain held by the
Purchasers and if less than 20% of the Shares are then outstanding and held by Purchasers, 66-2/3% of 

  
 4 

 
the Shares and exercised and unexercised Warrant Shares then outstanding that have not been resold pursuant to an effective registration statement under the Securities Act or Rule 144 of the
Securities Act. 
 “Trading Day” means (i) a day on which the Common Stock is traded
on a Trading Market, or (ii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported by the Pink OTC Markets, Inc. (or any similar organization or agency
succeeding to its functions of reporting prices); provided, that in the event that the Common Stock is not listed or quoted as set forth in (i) and (ii) hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, NYSE Amex Equities, the NASDAQ
National Market, the NASDAQ SmallCap Market or OTC Bulletin Board on which the Common Stock is listed or quoted for trading on the date in question. 
 “Transfer Agent” means American Stock Transfer & Trust Company LLC with offices at 6201 15th Avenue, Brooklyn, NY 11219, the current transfer agent for the Common Stock of
the Company. 
 “Transaction Documents” means this Agreement, the Warrants, the
Registration Rights Agreement, all exhibits and schedules hereto and thereto and any other documents or agreements executed in connection with the transactions contemplated hereunder. 

“Units” shall have the meaning ascribed to such term in Section 2.1. 

“VWAP” means, for any date, the price determined by the first of the following clauses that
applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTC Bulletin Board is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then reported in the “Pink
Sheets” published by Pink OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Shares then outstanding and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company. 
 “Warrant” means the common stock
purchase warrant, which shall be in the form attached hereto as Exhibit C and shall grant the holder thereof the right to purchase one share of Common Stock at an exercise price equal to the Warrant Exercise Price. 

“Warrant Exercise Price” means an exercise price equal to $0.25. 

“Warrant Shares” means the shares of Common Stock issuable upon exercise of the
Warrants. 

  
 5 

 ARTICLE II. 
 PURCHASE AND SALE 
 2.1 Closing. On the Closing Date, upon the terms
and subject to the conditions set forth herein relating to the offering (the “Offering”) by the Company of up to an aggregate of 14,500,000 units (the “Units”), each consisting of one share of Common
Stock and one Warrant, the Company agrees to sell to the Purchasers, and the Purchasers severally, and not jointly, agree to purchase from the Company, that number of Units equal to (a) the Subscription Amount (b) divided by the Per Unit
Purchase Price. On the Closing Date, each Purchaser shall deliver to the Escrow Agent via wire transfer or certified check of immediately available funds equal to such Purchaser’s Subscription Amount, the Company shall deliver to each Purchaser
its respective Shares and Warrants as set forth in Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and
conditions set forth in Section 2.2 and Section 2.3, the Closing shall occur at the offices of GT or such other location as the parties shall mutually agree. 

2.2 Deliveries. 
 (a) Company Deliveries. On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser or a duly designated representative thereof the following:

(i) this Agreement duly executed by the Company; 

(ii) a legal opinion of Company Counsel, substantially in the form of Exhibit D attached hereto; 

(iii) a legal opinion of Ellenoff Grossman & Schole LLP, substantially in the form of Exhibit E attached
hereto; 
 (iv) a copy of irrevocable instructions to the Transfer Agent instructing the Transfer Agent to
deliver, on an expedited basis, a certificate evidencing that the Purchaser’s Shares registered in the name of such Purchaser; 
 (v) a Warrant registered in the name of such Purchaser pursuant to which such Purchaser shall have the right to purchase a number of shares of Common Stock equal to 100% of the number of such
Purchaser’s Shares at the Warrant Exercise Price; 
 (vi) Lock-Up Agreements duly executed by each of the
directors and officers of the Company; 
 (vii) the Registration Rights Agreement duly executed by the Company;
and 
 (viii) the Escrow Agreement duly executed by the Company and the Escrow Agent. 

  
 6 

 (b) Purchaser Deliveries. On or prior to the Closing Date, each
Purchaser shall deliver or cause to be delivered to the Company the following: 
 (i) this Agreement duly
executed by such Purchaser; 
 (ii) such Purchaser’s Subscription Amount by wire transfer to the account as
specified in writing by the Company; and 
 (iii) the Registration Rights Agreement duly executed by such
Purchaser. 
 2.3 Closing Conditions. 

(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being
met: 
 (i) the accuracy in all material respects when made and on the Closing Date of the representations and
warranties of the Purchasers contained herein (unless as of a specific date therein, in which case they shall be accurate in all material respects as of such date); 

(ii) all obligations, covenants and agreements of the Purchasers required to be performed at or prior to the Closing Date
shall have been performed; 
 (iii) no proceeding challenging this Agreement or the transactions contemplated
hereby, or seeking to prohibit, alter, prevent or materially delay the Closing, shall have been instituted before any court or governmental body, or agency and shall be pending; 

(iv) the sale of the Securities by the Company shall not be prohibited by any law or governmental order or regulation;

 (v) all necessary consents, approvals, licenses, permits, orders and authorizations of, or registrations,
declarations and filings with, any governmental or administrative agency with respect to any of the transactions contemplated hereby shall have been duly obtained or made and shall be full force and effect; and 

(vi) the delivery by the Purchasers of the items set forth in Section 2.2(b) of this Agreement. 

(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following
conditions being met: 
 (i) the accuracy in all material respects when made and on the Closing Date of the
representations and warranties of the Company contained herein (unless as of a specific date therein, in which case they shall be accurate in all material respects as of such date); 

  
 7 

 (ii) all obligations, covenants and agreements of the Company required to be
performed at or prior to the Closing Date shall have been performed; 
 (iii) the delivery by the Company of the
items set forth in Section 2.2(a) of this Agreement; 
 (iv) there shall have been no Material
Adverse Effect with respect to the Company since the date hereof; and 
 (v) from the date hereof to the Closing,
trading in the Common Stock shall not have been suspended by the SEC or the Company’s principal Trading Market (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the
Closing), and, at any time prior to the Closing, trading in securities generally as reported by Bloomberg shall not have been suspended or limited, nor shall a banking moratorium have been declared either by the United States or New York State
authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case,
in the reasonable judgment of each Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing. 

2.4 Acceptance of Subscription. The Company shall have no obligation hereunder until the Company shall execute and deliver to each
of the Purchasers an executed copy of this Agreement. If this subscription is rejected or the Offering is terminated, in each case, prior to execution and delivery of this Agreement by the Company, this Agreement and all other documents executed by
each of the Purchasers shall thereafter be of no further force or effect. 
 ARTICLE III. 

REPRESENTATIONS AND WARRANTIES 
 3.1 Representations and Warranties of the Company. Except as set forth under the corresponding section of the disclosure schedules attached hereto (the “Disclosure
Schedules”), which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the
Company hereby makes the representations and warranties set forth below to each Purchaser as of the date hereof and as of the Closing Date (unless as of a specific date therein, in which case they are made as of such date): 

(a) Subsidiaries. The Company has no subsidiaries. 

(b) Organization and Qualification. The Company is duly incorporated, validly existing and in good standing under
the laws of the State of Delaware, with the requisite power and authority to own and use its properties and assets and to carry on its 

  
 8 

 
business as currently conducted. The Company is not in violation or default of any of the provisions of its certificate of incorporation and bylaws. The Company is duly qualified to conduct
business and is in good standing as a foreign corporation in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing,
as the case may be, would not have or reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations,
assets, business, prospects or condition (financial or otherwise) of the Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document (any of (i), (ii) or (iii), a “Material Adverse Effect”), and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and
authority or qualification. 
 (c) Authorization; Enforcement. The Company has the requisite corporate
power and authority to enter into and to consummate the transactions contemplated by each of the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of each of the Transaction
Documents by the Company and the consummation by it of the transactions contemplated thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, its board of directors or its
stockholders in connection therewith other than the Required Approvals. Each Transaction Document has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms except (i) as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation and other similar laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies,
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law (collectively, the “Equitable Exceptions”). 

(d) No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate of incorporation or bylaws, or (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company debt or otherwise) or other understanding to which the Company is a party or
by which any property or asset of the Company is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or
reasonably be expected to result in a Material Adverse Effect. 

  
 9 

 (e) Filings, Consents and Approvals. The Company is not required to
obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery
and performance by the Company of the Transaction Documents, other than (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) filings required pursuant to the Registration Rights Agreement and the Selling
Agent Warrants and (iii) the filing of Form D with the SEC pursuant to Regulation D under the Securities Act and (iv) and such filings as are required to be made under applicable state securities laws (collectively, the
“Required Approvals”). 
 (f) Valid Issuance. The Shares are duly authorized and,
when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in
the Transaction Documents. The Warrants have been duly and validly authorized. Upon the due exercise of the Warrants, the Warrant Shares will be validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company other
than restrictions on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized capital stock a sufficient number of shares of Common Stock for issuance upon the exercise of the Warrants. 

(g) Capitalization. The capitalization of the Company is as described in the SEC Reports. The Company has not
issued any capital stock since its most recently filed periodic report under the Exchange Act other than pursuant to the exercise of employee stock options under the Company’s stock option plans, the issuance of shares of Common Stock to
employees pursuant to existing employee benefit plans or pursuant to the conversion or exercise of outstanding Common Stock Equivalents. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to
participate in the transactions contemplated by the Transaction Documents. Except (i) as a result of the purchase and sale of the Shares, (ii) as set forth in the SEC Reports, or (iii) as set forth on Schedule 3.1(g), there are
no outstanding options, warrants, rights to subscribe to, calls or commitments of any kind whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock, or contracts, commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. The issuance and sale of the
Securities will not obligate the Company to issue shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or
reset price under such securities. All of the outstanding shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such
outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for 

  
 10 

 
or purchase securities. Any statements in the SEC Reports regarding employee and director stock options are accurate in all material respects. There are no stockholders agreements, voting
agreements or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders. 

(h) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other
documents required to be filed by it under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (the foregoing materials, including the exhibits thereto and
documents incorporated by reference therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to
the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the SEC promulgated thereunder,
and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in
effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis during the periods involved, except
as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the
Company as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. 

(i) Material Changes. Since the date of the latest audited financial statements included within the SEC Reports,
except as specifically disclosed in subsequent SEC Reports filed prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required
to be reflected in the Company’s financial statements pursuant to GAAP or required to be disclosed in filings made with the SEC, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any
dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock, and (v) the Company has not issued any equity securities to any officer,
director or Affiliate, except pursuant to existing Company stock option or stock plans. Except for the issuance of the Securities contemplated by this Agreement or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence
or development has occurred or exists with respect to the 

  
 11 

 
Company or its business, properties, operations, assets or financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this
representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day prior to the date that this representation is made. The Company does not have pending before the SEC any request for confidential treatment
of information. 
 (j) Litigation. Except as disclosed in the SEC Reports, there is no action, suit,
inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its properties before or by any court, arbitrator, governmental or administrative agency or
regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”) which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the
Securities or (ii) would, if there were an unfavorable decision, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. No director or officer of the Company is or has been the subject of any
Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty within the last five (5) years. There has not been, and to the knowledge of the Company, there is not pending or
contemplated, any investigation by the SEC involving the Company or to the knowledge of the Company any current or former director or officer of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company under the Exchange Act or the Securities Act. 
 (k) Labor
Relations. No material labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company which could reasonably be expected to result in a Material Adverse Effect. None of the
Company’s employees is a member of a union that relates to such employee’s relationship with the Company, and the Company is not a party to a collective bargaining agreement. The Company believes that its relationships with its employees
is good. No executive officer, to the knowledge of the Company, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition
agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company to any liability with respect to any of the foregoing
matters. The Company is in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in
compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (l) Compliance. The Company (i) neither is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a
default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which
it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is not in violation of any order of any court, arbitrator or governmental 

  
 12 

 
body, and (iii) neither is nor has been in violation of any statute, rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws
applicable to its business, except in each case as could not reasonably be expected to have a Material Adverse Effect. 
 (m) Regulatory Permits. The Company possesses all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary to conduct its
business as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material Permits”), and the Company has not received any
notice of proceedings relating to the revocation or modification of any Material Permit. 
 (n) Title to
Assets. The Company owns no real property and has good and marketable title to all owned personal property that is material to its business, free and clear of all Liens, except for Liens as do not materially affect the value of such property and
do not materially interfere with the use made and proposed to be made of such property by the Company and Liens for the payment of federal, state or other taxes, the payment of which is neither delinquent nor subject to penalties. Any real property
and facilities held under lease by the Company are held by it under valid, subsisting and enforceable leases of which the Company is in compliance, except as could not reasonably be expected to result in a Material Adverse Effect. 

(o) Patents and Trademarks. The Company has, or has rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights that are necessary or material for use in connection with its business as described in the
SEC Reports, except for such instances, if any, where the failure to have such rights could not reasonably be expected to have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). The Company has not
(i) received a notice (written or otherwise) that any of the Intellectual Property Rights used by the Company violate or infringe upon the rights of any Person, or (ii) received a written invitation to license any Intellectual Property
Rights of a Person in order to avoid such a violation or infringement. To the knowledge of the Company, all such Intellectual Property Rights are enforceable (subject only to the Equitable Exceptions) and there is no existing infringement by another
Person of any of the Intellectual Property Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all of the Intellectual Property Rights, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
 (p) Insurance. The
Company is insured by insurers of recognized financial responsibility against such losses and risks, including, without limitation, products liability, and in such amounts as are prudent and customary in the businesses in which the Company is
engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount. To the best knowledge of the Company, such insurance contracts and policies are accurate and complete. The

  
 13 

 
Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business on terms consistent with market for the Company’s line of business. 

(q) Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or
directors of the Company, or any person who served as an officer or director in the 12 months prior to the date of this Agreement, and, to the knowledge of the Company, none of the employees of the Company is presently a party to any transaction
with the Company (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from,
or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or
partner, in each case in excess of $120,000 other than (i) for payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) for other equity compensation or
employee benefits, including, without limitation, stock option agreements under any stock option plan of the Company. 
 (r) Sarbanes-Oxley; Internal Accounting Controls. The Company is in material compliance with all provisions of the Sarbanes-Oxley Act of 2002 which are applicable to it as of the Closing Date. The
Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization,
and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company is made known to the certifying officers by others within those
entities, particularly during the period in which the Company’s most recently filed periodic report under the Exchange Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the
Company’s controls and procedures as of the date prior to the filing date of the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently
filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have
been no significant changes in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation S-K under the Exchange Act) or, to the knowledge of the Company, in other factors that could significantly affect the
Company’s internal controls. 

  
 14 

 (s) Certain Fees. Except for the fees and expenses of the Selling
Agent and the Selling Agent Warrants, no brokerage or finder’s fees or commissions are or will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with
respect to the transactions contemplated by the Transaction Documents. 
 (t) Private Placement. Assuming
the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated
hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market. 
 (u) Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be an Affiliate of, an “investment company”
within the meaning of the Investment Company Act of 1940, as amended, and the Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration thereunder. 

(v) Registration Rights. Other than each of the Purchasers pursuant to the Registration Rights Agreement and the
Selling Agent pursuant to the Selling Agent Warrants, no Person has any right to cause the Company to effect the registration under the Securities Act of any securities of the Company. 

(w) Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(g) of the
Exchange Act, and the Company has taken no action designed to terminate, or which to its knowledge is likely to have the effect of terminating, the registration of the Common Stock under the Exchange Act, nor has the Company received any
notification that the SEC is contemplating terminating such registration. The Company has not, in the twelve (12) months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or
quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
with all such listing and maintenance requirements. 
 (x) Application of Takeover Protections. The
Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company’s Certificate of Incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities. 

(y) Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the
Transaction Documents, the Company confirms that 

  
 15 

 
neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes material, non-public
information. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities of the Company. The disclosure provided by or on behalf of the Company to the Purchasers
regarding the Company, its business and the transactions contemplated hereby, including the representation and warranties made herein and the Disclosure Schedules, do not contain any untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof. 
 (z) No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, neither the Company, nor any Affiliate of the Company
or any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
prior offerings by the Company for purposes of the Securities Act which would require the registration of any such securities under the Securities Act or any applicable stockholder approval provisions, including, without limitation, under the rules
and regulations of any Trading Market on which any of the securities of the Company are listed or designated. 

(aa) Solvency. Based on the financial condition of the Company as of the Closing Date after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, the Company’s fair saleable value of its assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and
other liabilities (including known contingent liabilities) as they mature. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in
respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. The SEC Reports set forth as of the dates thereof all outstanding secured and unsecured Indebtedness of the Company or for which the Company has commitments. For the purposes of this Agreement, “Indebtedness”
shall mean (X) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (Y) all guaranties, endorsements and other contingent obligations in
respect of indebtedness of others, whether or not the same are or should be reflected in the Company’s balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (Z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. The Company is not in default with respect to any
Indebtedness. 

  
 16 

 (bb) Tax Status. Except for matters that would not, individually or
in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company (i) has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon,
and (ii) has no knowledge of a tax deficiency which has been asserted or threatened against the Company. 

(cc) No General Solicitation. Neither the Company nor any Person acting on behalf of the Company has offered or
sold any of the Securities by any form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain other “accredited investors” within the meaning of Rule 501 under the
Securities Act. 
 (dd) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of the
Company, any agent or other person acting on behalf of the Company, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity,
(ii) made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company
(or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended 

(ee) Accountants. The Company’s accountant firm is set forth in the SEC Reports. To the Company’s
knowledge, such accountant firm (i) is a registered public accounting firm as required by the SEC and (ii) shall express its opinion with respect to the financial statements to be included in the Company’s Annual Report on Form 10-K
for the year ending December 31, 2010. 
 (ff) No Disagreements. There are no disagreements of any
kind presently existing, or reasonably anticipated by the Company to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company, and the Company is current with respect to any fees owed to its
accountants and lawyers which could affect the Company’s ability to perform any of its obligations under any of the Transaction Documents. 
 (gg) Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm’s length
purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect
to the Transaction Documents and the transactions contemplated hereby and any advice given by any of the Purchasers or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated
thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based solely
on the independent evaluation of the transactions contemplated hereby by the Company and its representatives. 

  
 17 

 (hh) Manipulation of Price. The Company has not, and to its
knowledge no one acting on its behalf has (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of
the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other
securities of the Company, other than, in the case of clauses (ii) or (iii), compensation paid to the Selling Agent in connection with the placement of the Securities. 

(ii) Stock Option Plans. Each stock option granted by the Company under the Company’s stock option plan was
granted (i) in accordance with the terms of the Company’s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under
GAAP and applicable law. No stock option granted under the Company’s stock option plan has been backdated. The Company has not knowingly granted, and there is and has been no Company policy or practice to knowingly grant, stock options prior
to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its financial results or prospects. 

(jj) Disclaimer of Other Representations and Warranties; Knowledge. 

(i) The Company does not make and has not made, and shall not be deemed to have made, any representations or warranties
relating to the Company’s business or assets, or otherwise in connection with the transactions contemplated hereby, other than those expressly set forth herein which are made by the Company. Without limiting the generality of the foregoing, the
Company has not made and shall not be deemed to have made, any representations or warranties as to the information contained in any presentation relating to the Company in connection with the transactions contemplated hereby, and no statement made
in any such presentation shall be deemed a representation or warranty hereunder or otherwise. It is understood that any cost estimates, projections or other predictions, any data, and any financial information or presentations by the Company’s
management are not and shall not be deemed to be or to include representations or warranties of Company (it being understood that this subsection shall not be deemed to limit the representations and warranties contained herein, including, without
limitation, those with respect to the SEC Reports). No person has been authorized by the Company to make any representation or warranty relating to the Company or otherwise in connection with the transactions contemplated hereby and, if made, such
representation or warranty must not be relied upon as having been authorized by the Company. 

  
 18 

 (ii) Whenever a representation or warranty made by the Company herein refers
to the knowledge of the Company, such knowledge shall be deemed to consist only of the actual knowledge of the officers and directors of the Company. 
 3.2 Representations and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as of the date hereof and as of the Closing Date to the
Company as follows: 
 (a) Organization; Authority. Such Purchaser has full power and authority to enter
into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out the obligations thereunder. Each Purchaser not a natural person is duly organized, validly existing and in good standing under the laws of
the jurisdiction of its organization with full right, corporate or partnership power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations thereunder. The
execution, delivery and performance by each Purchaser that is not a natural person of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or similar action on the part of such Purchaser. 

(b) Execution. Each Transaction Document to which such Purchaser is a party has been duly executed by such
Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law. 

(c) Restricted Securities. Such Purchaser understands that the Securities are restricted securities and have not
been registered under the Securities Act or any applicable state securities law and, except as set forth in the Registration Rights Agreement, the Company has no present or future obligation to register the Securities under the Securities Act or any
state securities laws. Such Purchaser understands that the offering and sale of the Securities is intended to be exempt from registration under the Securities Act, by virtue of Section 4(2) thereof and the provisions of Regulation D promulgated
thereunder, based in part, upon the representations, warranties and agreements of such Purchaser contained in this Agreement. Subject to the terms hereunder, legends shall be placed on the Securities to the effect that they have not be registered
under the Securities Act or applicable state securities laws and appropriate notations thereof will be made in the Company’s stock books. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present
time, is able to afford a complete loss of such investment. 
 (d) Own Account. Such Purchaser is
acquiring the Securities solely for such Purchaser’s own account and not with a view to or for distributing or reselling such 

  
 19 

 
Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the
Securities Act or any applicable state securities law and has no direct or indirect, formal or informal, agreement, arrangement or understanding with any other persons regarding the distribution of such Securities in violation of the Securities Act
or any applicable state securities law, and has no plans to enter into any such agreement or arrangement. For the avoidance of doubt, this representation and warranty shall not limit such Purchaser’s right to sell the Securities in compliance
with applicable federal and state securities laws. 
 (e) Purchaser Status. At the time such Purchaser was
offered the Securities, it was, and at the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i) an “accredited investor” as defined in Rule 501(a) under the Securities Act or (ii) a
“qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act. Such Purchaser is not required to be registered as a broker-dealer under Section 15 of the Exchange Act. 

(f) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such
knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such
Purchaser is able to bear the economic risk of the investment in the Securities and, at the present time, has a sufficient net worth to sustain a complete loss of such investment in the Company in the event such a loss should occur. 

(g) General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 (h) Access to Information. Such Purchaser acknowledges that it has had access to and has reviewed the
Disclosure Schedules, the SEC Reports and all other documents pertaining to the Offering, and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company
concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business,
properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is
necessary to make an informed investment decision with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser or its representatives or counsel shall modify, amend or affect the
Purchaser’s right to rely on the truth, accuracy and completeness of the Disclosure Schedules and the Company’s representations and warranties contained in the Transaction Documents. 

  
 20 

 (i) Certain Transactions and Confidentiality. Other than
consummating the transactions contemplated hereunder, such Purchaser has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, executed any purchases or sales, including Short
Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) as of the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set
forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement,
such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions. 

(j) No Conflict. The execution and delivery of this Agreement and the transactions and contemplated herein by
such Purchaser and the consummation of the transactions contemplated hereby and thereby will not conflict with or result in any violation of or default by such Purchaser (with or without notice or lapse of time, or both) under, or give rise to a
right of termination, cancellation or acceleration of any obligation or to a loss of a material benefit under (i) any provision of the organizational documents of such Purchaser, (ii) any material agreement or instrument, permit,
franchise, or license or (iii) any judgment, order, statute, law, ordinance, rule or regulations, applicable to such Purchaser or its respective properties or assets. 

(k) Brokers. Each Purchaser has not retained, utilized or been represented by any broker or finder in
connection with the transactions contemplated by this Agreement. 
 (l) Disclosure. Such Purchaser
acknowledges and agrees that the Company does not make and has not made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.1 hereof. 

(m) Address. Such Purchaser’s address on the signature page hereto indicates the true state of residence of
such Purchaser. 

  
 21 

 ARTICLE IV. 
 OTHER AGREEMENTS OF THE PARTIES 
 4.1 Transfer Restrictions.

 (a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection
with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may
require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the
effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration
Rights Agreement and shall have the rights and obligations of a Purchaser hereunder and thereunder. 
 (b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in substantially the following form: 
 THIS SECURITY [AND THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE] HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY,] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER
LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT. 
 (c) The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant a security interest in some or all
of the Securities to a financial institution that is an “accredited investor” as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and the Registration Rights Agreement

  
 22 

 
and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject
to approval of the Company, and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Prompt notice shall be given to the Company of such a pledge or transfer. At the appropriate
Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities
are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to
appropriately amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder. 
 (d) Certificates evidencing the Shares and the Warrant Shares shall not contain any legend, including the legend set forth in Section 4.1(b) above, (i) following the resale of the Shares
or Warrant Share pursuant to an effective registration statement under the Securities Act covering the resale of such Shares or Warrant Shares, (ii) following any resale of such Shares or Warrant Shares pursuant to Rule 144,
(iii) if such Shares or Warrant Shares are eligible for resale under Rule 144 without the requirement that the Company be in compliance with current public information or volume limitations, or (iv) if such legend is not required
under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC). The Company agrees that following the time when a legend is no longer required under this
Section 4.1(d), it will, no later than three (3) Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Shares or Warrant Shares issued with a restrictive legend (such
date, the “Legend Removal Date”), and receipt by the Company and Company counsel of a written request that the Company remove the legend from such certificate, deliver or cause to be delivered to such Purchaser or such
Purchaser’s transferee, as applicable, a certificate representing such Shares or Warrant Shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to any transfer agent
of the Company that enlarge the restrictions on transfer set forth in this Section. Notwithstanding anything to the contrary contained herein, the Company shall not be required to effect a removal of a restrictive legend to the extent such legend is
required under applicable requirements of the Securities Act, including any rule of the SEC promulgated thereunder, and judicial interpretations thereof. 

(e) In addition to such Purchaser’s other available remedies, the Company shall pay to a
Purchaser, in cash, as partial liquidated damages and not as a penalty, for each $2,000 of Shares or Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are submitted to the Transfer Agent) delivered for removal of the
restrictive legend and subject to Section 4.1(c), $10.00 per Trading Day for each Trading Day after the second
(2nd) Trading Day following the Legend Removal Date
until such certificate is delivered without a legend; provided, however, that such Purchaser has provided the Company with at least one (1) Trading Day’s prior written notice of such failure to deliver certificates without
legends; provided, further, that the Company shall 

  
 23 

 
not be obligated to pay any per Trading Day liquidated damages with respect to delays directly caused by a Force Majeure (but the Company shall use reasonable best efforts to remedy or overcome
such failures as promptly as possible). Nothing herein shall limit such Purchaser’s right to pursue actual damages for the Company’s failure to deliver certificates representing any Securities as required by the Transaction Documents, and
such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. 

(f) Each of the Purchasers, severally and not jointly with the other Purchasers, agrees that the removal of the
restrictive legend from certificates representing the Shares or the Warrant Shares as set forth in this Section 4.1(d)(i) or (ii) is predicated upon the Company’s reliance that such Purchaser will sell any such
Shares or Warrant Shares pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a Registration
Statement. 
 4.2 Furnishing of Information; Public Information. 

(a) Until the earlier of (i) such time as no Purchaser owns Securities or (ii) the Warrants expire, the Company
covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act. As long as any Purchaser owns
Securities, if the Company is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make publicly available in accordance with Rule 144(c) such information as is required for the Purchasers to
sell the Securities under Rule 144. The Company further covenants that it will take such further action as any holder of Securities may reasonably request, all to the extent required from time to time to enable such Purchaser to sell such Securities
without registration under the Securities Act within the limitation of the exemptions provided by Rule 144. 
 (b) At any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the Securities may be sold without the requirement for the
Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule 144, including, without limitation, Rule 144(i), if the Company shall fail for any reason to satisfy the current public information
requirement under Rule 144(c) (a “Public Information Failure”) then, in addition to such Purchaser’s other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a
penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to 1.0% of such Purchaser’s aggregate Subscription Amount which shall become due and owing on the day of a Public Information
Failure and on every thirtieth (30th) day thereafter
(pro rated for periods totaling less than thirty (30) days) until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer required for the Purchasers to
transfer the Shares and the Warrant Shares pursuant to Rule 144 (such payments, the “Public Information Failure Payments”). The Company shall be required to pay the Public Information Failure

  
 24 

 
Payments on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the third (3rd) Business Day after the event or failure giving rise to the
Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (pro
rated for partial months) until paid in full. Nothing herein shall limit such Purchaser’s right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief. The aggregate amount of Public Information Failure Payments shall not exceed 10% of a Purchaser’s aggregate Subscription Amount, less any
amounts paid pursuant to Section 2(b) of the Registration Rights Agreement. 
 4.3 Integration. The Company shall
not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require
the registration under the Securities Act of the sale of the Securities to the Purchasers or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require
stockholder approval of the sale of the Securities to the Purchasers unless stockholder approval is obtained before the closing of such subsequent transactions. 
 4.4 Securities Laws Disclosure; Publicity. The Company shall on the Trading Day immediately following the date hereof, issue a Current Report on Form 8-K , by 5:30 p.m. (New York City time)
(the “8-K Filing”), and press release, by 8:30 a.m. (New York City time) (the “Initial Press Release”), disclosing the material terms of the transactions contemplated hereby, and including the
Transaction Documents as exhibits thereto. From and after the issuance of such press release, the Company shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company, or any of its
respective officers, directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to
the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any
Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company that expressly identifies the individual Purchaser, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any
Purchaser, or include the name of any Purchaser in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except: (a) as required by federal securities law in connection with
(i) any registration statement contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents (including signature pages thereto) with the SEC and (b) to the extent such disclosure is required by
law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted under this clause (b). 

  
 25 

 4.5 Stockholder Rights Plan. No claim will be made or enforced by the Company or, to
the knowledge of the Company, any other Person that any Purchaser is an “acquiring person” under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement), stockholder rights
plan or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction
Documents. 
 4.6 Non-Public Information. Except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information that the Company believes constitutes
material non-public information, unless prior thereto such Purchaser shall have executed a written agreement with the Company regarding the confidentiality and use of such information. The Company understands and confirms that each Purchaser shall
be relying on the foregoing covenant in effecting transactions in securities of the Company. If a Purchaser (other than a holder of the Company’s Series D Convertible Preferred Stock) has received, from and after the time of the 8-K Filing, any
material, nonpublic information regarding the Company from the Company or any of its officers, directors, affiliates or agents, it may provide the Company with written notice thereof. The Company shall, within two (2) Trading Days of receipt of
such notice, make public disclosure of such material, nonpublic information. 
 4.7 Use of Proceeds. The Company shall
use the net proceeds from the sale of the Securities hereunder for working capital purposes and not for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the ordinary course of the Company’s
business and prior practices), to redeem any Company equity or equity-equivalent securities or to settle any outstanding litigation. 
 4.8 Indemnification of Purchasers. Subject to the provisions of this Section 4.8, the Company will indemnify and hold the Purchasers and their respective directors, officers,
shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a
Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating to
(a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against a Purchaser in any capacity, or any of them
or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of such
Purchaser’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser may have with any such stockholder or any violations by the

  
 26 

 
Purchaser of state or federal securities laws or any conduct by such Purchaser which constitutes fraud, gross negligence, willful misconduct or malfeasance). If any action shall be brought
against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of
its own choosing, reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the
expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to
employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party. The Company will not be
liable to any Purchaser Party under this Agreement (i) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (ii) to the extent, but only
to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements made by the Purchasers in this Agreement or in the other Transaction
Documents. 
 4.9 Reservation of Common Stock. As of the date hereof, the Company has reserved for issuance from its duly
authorized shares of Common Stock, and the Company shall continue to maintain such reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for issuance pursuant to the Transaction Documents
as may be required to fulfill its obligations under the Transaction Documents in full with respect to the issuance of the Shares and the Warrant Shares pursuant to any exercise of the Warrants. 

4.10 Trading Leak-Out. Each Purchaser, severally and not jointly with the other Purchasers, hereby covenants
and agrees that from the Trading Day immediately following the Exercise Date until 4:00 p.m. on the fifteenth
(15th) Trading Day immediately following the Exercise
Date, neither such Purchaser nor any of its Affiliates shall, on any Trading Day during such period, sell shares of Common Stock on the Trading Market in excess of 20% of the daily trading volume of the Common Stock on such Trading Day, as reported
on Bloomberg. 
 4.11 Subsequent Equity Sales. 

(a) Except for the exempt issuances forth in Section 4.11(b) below, from the date hereof until the earlier of
(i) June 30, 2011 and (ii) the date that is thirty (30) days after the Exercise Date (the “Restricted Period”), the Company shall not issue, enter into any agreement to issue or announce the issuance or
proposed issuance of any shares of Common Stock or Common Stock Equivalents (each, a “Subsequent Financing”). The Restricted Period shall be extended by that number of days equal to the number of Trading Days during the
Restricted Period on which (X) trading in the Common Stock is suspended by any Trading Market, (Y) the Registration Statement is not effective or (Z) the prospectus included in the Registration Statement may not be used by the
Purchasers for the resale of the Shares and the Warrant Shares. 

  
 27 

 (b) Notwithstanding the foregoing, the restrictions set forth in
Section 4.11(a) above shall not apply in respect of any of the following exempt issuances: 
 (i) the
issuance of the Warrant Shares; 
 (ii) the issuance of shares of Common Stock issuable upon exercise of the
Selling Agent Warrants; 
 (ii) the issuance of shares of Common Stock or options to purchase shares of Common
Stock to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee comprised of
the non-employee members of the Board of Directors established for such purpose; 
 (iii) the issuance of
securities upon the exercise or exchange of or conversion of any securities exercisable or exchangeable for, or convertible into, shares of Common Stock issued and outstanding on the date of this Agreement; provided that such securities have not
been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price thereof; 

(iv) the issuance of securities pursuant to acquisitions or strategic transactions approved by a majority of the
disinterested members of the Board of Directors; provided, that any such issuances shall be permitted to be made only to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an
asset in a business synergistic with the business of the Company and shall provide the Company with benefits in addition to the investment of funds; provided, however, that this exclusion shall not include a transaction in which the
Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities; and 
 (v) with the prior written consent of the Selling Agent, up to an amount of Common Stock and warrants equal to the difference between $2,900,000 and the aggregate Subscription Amounts hereunder, on the
same terms and conditions and prices as hereunder, with investors executing definitive agreements for the purchase of such securities and such transactions having closed on or before the earlier of (i) the Filing Deadline (as defined in the
Registration Rights Agreement) or (ii) the date that the Initial Registration Statement (as defined in the Registration Rights Agreement) is actually filed with the SEC. 
 4.12 Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it, nor any Affiliate acting on its behalf or pursuant to
any understanding with it will execute any purchases or sales, including Short Sales, of any of the Company’s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the Initial Press Release. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated

  
 28 

 
by this Agreement are publicly disclosed by the Company pursuant to the Initial Press Release, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and
the information included in the Transaction Documents and the Disclosure Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that
(i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly
announced pursuant to the Initial Press Release, (ii) no Purchaser shall be restricted or prohibited hereby from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the Initial Press Release and (iii) no Purchaser shall have any duty of confidentiality hereby to the Company after the issuance of the Initial Press
Release. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct
knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that
made the investment decision to purchase the Securities covered by this Agreement. 
 4.13 Form D; Blue Sky Filings. The
Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine
is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable securities or “Blue Sky” laws of the states of the United States, and shall provide evidence of such
actions promptly upon request of any Purchaser. 
 4.14 Delivery of Securities After Closing. The Company shall deliver,
or cause to be delivered, the respective Securities purchased by each Purchaser to such Purchaser within three (3) Trading Days of the Closing. 
 4.15 Acknowledgment of Dilution. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of its Common Stock, which dilution may be substantial
under certain market conditions. The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Shares and the Warrant Shares pursuant to the Transaction Documents,
are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect
that such issuance may have on the ownership of the other stockholders of the Company. 

  
 29 

 ARTICLE V. 
 MISCELLANEOUS 
 5.1 Termination. This Agreement may be terminated by
the Company and any Purchaser, as to such Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not
been consummated on or before December 31, 2010; provided, however, that such termination will not affect the right of any party to sue for any breach by the other party (or parties). 

5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all
transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities. 
 5.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 
 5.4 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of
(a) the date of transmission, if such notice or communication is delivered via e-mail or facsimile at the e-mail address or facsimile number set forth on the signature pages attached hereto prior to 5:30 p.m. (Eastern Time) on a Trading Day,
(b) the next Trading Day after the date of transmission, if such notice or communication is delivered via e-mail or facsimile at the e-mail address or facsimile number set forth on the signature pages attached hereto on a day that is not a
Trading Day or later than 5:30 p.m. (Eastern Time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as set forth on the signature pages attached hereto until changed by notice given in accordance with this Section 5.4. 

5.5 Entire Agreement. This Agreement and its exhibits and schedules constitutes the entire agreement among the Purchasers and the
Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. 
 5.6 Amendments; Waivers. Any provision of this Agreement may be waived, modified, supplemented or amended (either generally or in a particular instance and either retroactively or prospectively) in
a written instrument signed, in the case of an amendment, by the Company and the Supermajority Purchasers or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver of any default with

  
 30 

 
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. 
 5.7 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. 

5.8 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser. Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Securities, provided such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions hereof that apply to the “Purchasers”. 

5.9 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8. 
 5.10 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance
with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof, except to the extent that the application of the General Corporation Law of the State of Delaware is mandatorily applicable. Each party
agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and federal courts located in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts located in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any
of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding has
been commenced in an improper or inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right
to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. If any party shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the
prevailing party in such action or 

  
 31 

 
proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action
or proceeding. 
 5.11 Survival. The representations, warranties, agreements and covenants contained herein shall survive
the Closing and the delivery and/or exercise of the Securities, as applicable, for the applicable statute of limitations. 

5.12 Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is
delivered by e-mail or facsimile transmission, including e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. 
 5.13 Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the
terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ
an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed
the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 
 5.14 Replacement of Securities. If any certificate or instrument evidencing any of the Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange
and substitution for and upon cancellation thereof, or in lieu of and substitution therefore, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and customary
and reasonable indemnity, if requested. The applicants for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Securities. If a replacement
certificate or instrument evidencing Securities is requested due to a mutilation thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement Security. 

5.15 Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of
damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of
obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 

  
 32 

 5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to
any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to
be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person under any law (including, without limitation, any bankruptcy
law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred. 
 5.17 Independent Nature of Purchasers’
Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance of the
obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an
association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to
be joined as an additional party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in their review and negotiation of the Transaction Documents. For reasons of administrative convenience only,
each Purchaser and its respective counsel have chosen to communicate with the Company through GT. GT does not represent any of the Purchasers and only represents the Selling Agent. The Company has elected to provide all Purchasers with the same
terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. 
 5.18 Liquidated Damages. The Company’s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and
shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall
have been canceled. 
 5.19 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action
or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. 

5.20 Construction. 
 (a) The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction to the
effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto. 

  
 33 

 (b) Each and every reference to share prices and shares of Common Stock in
any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement. 

[SIGNATURE PAGE FOLLOWS] 

  
 34 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. 
  

					
	CAMBRIDGE HEART, INC.	    	Address for Notice:
			
	By:	 	       /s/ Ali Haghighi-Mood
	    	100 Ames Pond Drive
	Name:	 	Ali Haghighi-Mood	    	Tewksbury, MA 01876
	Title:	 	President and Chief Executive Officer	    	Attn: President
		
	With a copy to (which shall not constitute notice):	    	 Nutter, McClennen & Fish LLP
 155 Seaport Blvd.
 Boston, MA 02210

Attn: Michelle L. Basil, Esq.

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
 SIGNATURE PAGE FOR PURCHASERS FOLLOW]

 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART 

SECURITIES PURCHASE AGREEMENT] 
 IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 

 

					
	Name of Investing Entity or Person:	 	  
	 	
			
	Signature of Authorized Signatory of	 		 	
	Investing Entity or Person:	 	  
	 	
			
	Name of Authorized Signatory:	 	  
	 	
			
	Title of Authorized Signatory:	 	  
	 	
			
	Email Address of Authorized Signatory:	 	  
	 	
		
	Address for Notice of Investing Entity or Person:	 	
			
	  
	 		 	
			
	  
	 		 	
			
	  
	 		 	
	
	Address for Delivery of Securities for Investing Entity or Person (if not same as above):
			
	  
	 		 	
			
	  
	 		 	
			
	  
	 		 	
			
	Subscription Amount:
$                        	 		 	
			
	Shares:
                                         
         	 		 	
			
	Warrant Shares:
                                    	 		 	

 EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]  

 SCHEDULE I 

 

									
	 Purchaser Name
	  	Subscription
Amount	 	  	Purchaser Shares	 
	 George M. Abraham
	  	$	50,000	  	  	 	250,000	  
	 James E. Anderson
	  	$	50,000	  	  	 	250,000	  
	 Jay R. Angle
	  	$	200,000	  	  	 	1,000,000	  
	 Anthony Athanas, Jr.
	  	$	75,000	  	  	 	375,000	  
	 G. Hervey Bathurst
	  	$	75,000	  	  	 	375,000	  
	 John Blum, Jr.
	  	$	40,000	  	  	 	200,000	  
	 Michael Brodherson
	  	$	50,000	  	  	 	250,000	  
	 Bunkap Industries, Inc.
	  	$	75,000	  	  	 	375,000	  
	 Virginia Cahal
	  	$	25,000	  	  	 	125,000	  
	 Francis Chan and Jeffrey Chan, JTWROS
	  	$	25,000	  	  	 	125,000	  
	 Alan David Cohen
	  	$	20,000	  	  	 	100,000	  
	 Charles and Sandra Curtis, JTWROS
	  	$	40,000	  	  	 	200,000	  
	 Jason Curtis
	  	$	30,000	  	  	 	150,000	  
	 Arthur Dunkin
	  	$	40,000	  	  	 	200,000	  
	 Steven Etra
	  	$	250,000	  	  	 	1,250,000	  
	 Brenda Forwood
	  	$	25,000	  	  	 	125,000	  
	 Frederick Reese Freyer
	  	$	25,000	  	  	 	125,000	  
	 Frank J. Garofalo
	  	$	80,000	  	  	 	400,000	  
	 Gunther Motor Company of Plantation, Inc.
	  	$	50,000	  	  	 	250,000	  
	 Constantine Hagepanos
	  	$	25,000	  	  	 	125,000	  
	 Gregory Harrison
	  	$	100,000	  	  	 	500,000	  
	 Robert Henely
	  	$	25,000	  	  	 	125,000	  
	 Ryan Hogan
	  	$	80,000	  	  	 	400,000	  

									
	 	  	 	 	  	 	 
	 Stephen Holzel
	  	$	25,000	  	  	 	125,000	  
	 Francis Howard
	  	$	150,000	  	  	 	750,000	  
	 Daniel Hudson, IRA
	  	$	25,000	  	  	 	125,000	  
	 Intermark, LLC
	  	$	50,000	  	  	 	250,000	  
	 ISeeFitPeople, Inc.
	  	$	25,000	  	  	 	125,000	  
	 Robert Jacobs and Susan Jacobs, JTWROS
	  	$	25,000	  	  	 	125,000	  
	 James Krag, M.D.
	  	$	25,000	  	  	 	125,000	  
	 Stephen Leppo
	  	$	25,000	  	  	 	125,000	  
	 Craig Lindberg
	  	$	25,000	  	  	 	125,000	  
	 John D. Marks
	  	$	25,000	  	  	 	125,000	  
	 Luis F. Martins
	  	$	200,000	  	  	 	1,000,000	  
	 Patrick William O’Reilly
	  	$	50,000	  	  	 	250,000	  
	 Osiris Investment Partners, L.P.
	  	$	225,000	  	  	 	1,125,000	  
	 Michael Pantelis
	  	$	25,000	  	  	 	125,000	  
	 John R. Rogers, IRA
	  	$	50,000	  	  	 	250,000	  
	 John R. Rogers
	  	$	50,000	  	  	 	250,000	  
	 John J. Shaw
	  	$	100,000	  	  	 	500,000	  
	 Chris Sidhilall
	  	$	25,000	  	  	 	125,000	  
	 John Sloan, Jr.
	  	$	40,000	  	  	 	200,000	  
	 Gerald and Seena Sperling, JTWROS
	  	$	30,000	  	  	 	150,000	  
	 F. Richard Stark
	  	$	20,000	  	  	 	100,000	  
	 M.R. Stephenson
	  	$	100,000	  	  	 	500,000	  
	 Raymond Tinney, IRA
	  	$	40,000	  	  	 	200,000	  
	 Theodore W. VanVick
	  	$	25,000	  	  	 	125,000	  
	 James Walker
	  	$	40,000	  	  	 	200,000	  
	 Robert Zens
	  	$	25,000	  	  	 	125,000Registration Rights Agreement

 Exhibit 10.2 
 REGISTRATION RIGHTS AGREEMENT 
 This Registration Rights Agreement
(the “Agreement”) is made and entered into as of this 20th day of December, 2010, by and among Cambridge Heart, Inc., a Delaware corporation (the “Company”), and the Purchasers named in that certain
Securities Purchase Agreement, dated as of December 20, 2010, by and among the Company and the purchasers signatory thereto (the “Purchase Agreement”). 
 The parties hereby agree as follows: 
 1. Certain Definitions. 

As used in this Agreement, the following terms shall have the following meanings: 

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person as such terms are used in and construed under Rule 144 under the Securities Act. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by
the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser. 
 “Business
Day” means any day except Saturday, Sunday and any day which is a federal legal holiday or a day on which banking institutions in New York City are authorized or required by law or other governmental action to close. 

“Common Stock” means the Company’s common stock, par value $0.001 per share, and any other class of
securities into which such securities may hereafter have been reclassified or changed into. 
 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

“Prospectus” means the prospectus included in any Registration Statement (including, without limitation, a
prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated under the Securities Act), as amended or supplemented by any prospectus
supplement thereto, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the Prospectus, including post-effective amendments and
all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

“Purchasers” means the Purchasers identified in the Purchase Agreement and any Affiliate or permitted transferee
of any Purchaser who is a subsequent holder of any Warrants or Registrable Securities. 
 “Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration Statement or similar document in compliance with the Securities Act (as defined below), and the
declaration or ordering of effectiveness of such Registration Statement or document. 

  
 1 

 “Registrable Securities” means (i) the Shares, (ii) the
Warrant Shares and (iii) any other securities issued or issuable with respect to or in exchange for Registrable Securities; provided, that a security held by a Purchaser shall cease to be a Registrable Security upon (A) a sale by
such Purchaser pursuant to a Registration Statement or Rule 144 under the Securities Act or (B) such security becoming eligible for sale by such Purchaser pursuant to Rule 144 without volume limitations. 

“Registration Statement” means any registration statement or statements of the Company filed under the Securities
Act and (in each case) the related Prospectus that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement (including each of the Registration Statements referred to in Section 2), amendments and
supplements to each such Registration Statement and Prospectus, including pre- and post-effective amendments, all exhibits and all material filed and incorporated by reference or deemed to be incorporated by reference in each such Registration
Statement. 
 “Required Purchasers” means Purchasers holding a majority of the Registrable Securities.

 “Rule 416” and “Rule 429” mean “Rule 416” and
“Rule 429,” respectively, each as promulgated by the SEC pursuant to the Securities Act, as either such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially
the same effect as such Rule. 
 “SEC” means the U.S. Securities and Exchange Commission. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 “Shares” means the shares of Common Stock issued to the Purchasers pursuant to the
Purchase Agreement and any shares of Common Stock issued or issuable to the Purchasers upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. 

“Warrants” means the Warrants issued to the Purchasers pursuant to the Purchase Agreement. 

“Warrant Shares” means the shares of Common Stock issuable upon the exercise of the Warrants. 

2. Registration. 
 (a) Registration Statement. Promptly following the closing of the purchase and sale of the securities contemplated by the Purchase Agreement (the “Closing Date”) but no later than
January 31, 2011 (or, if later, thirty (30) days after the Closing Date) (the “Filing Deadline”), the Company shall prepare and file with the SEC a Registration Statement covering the resale of the Registrable Securities.
Such Registration Statement shall be on Form S-1 or Form S-3, as available, or other appropriate form in accordance herewith and shall include the plan of distribution attached hereto as Exhibit A; provided, however, that no Purchaser shall
be named as an “underwriter” in the Registration Statement without the Purchaser’s prior written consent. Such Registration Statement also shall cover, to the extent allowable under the

  
 2 

 
Securities Act (including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the
Registrable Securities. A copy of the initial filing of the Registration Statement (and each pre-effective amendment thereto) shall be provided to the Purchasers and their counsel at least three (3) Business Days prior to filing. On or before
April 15, 2011 (the “Updating Deadline”), the Company shall prepare and file with the SEC an amendment to the initial Registration Statement including such information related to the Company’s fiscal year ended
December 31, 2010 as is required in order for the Registration Statement to comply with the requirements of Form S-1 or Form S-3, as the case may be, as of the date of filing of such amendment (the “Updating Amendment”).

 (b) If a Registration Statement covering the Registrable Securities is not filed with the SEC on or prior to the Filing
Deadline, the Company will make pro rata payments to each Purchaser, as liquidated damages and not as a penalty, in an amount equal to 1.0% of the aggregate purchase price paid by such Purchaser pursuant to the Purchase Agreement for each 30-day
period or pro rata for any portion thereof following the Filing Deadline for which no Registration Statement is filed with respect to the Registrable Securities. If a Registration Statement covering the Registrable Securities is not declared
effective by the SEC on or before the Effectiveness Deadline (as defined below), other than as a result of limitations imposed by the SEC, the Company will make pro rata payments to each Purchaser, as liquidated damages and not as a penalty, in an
amount equal to 1.0% of the aggregate purchase price paid by such Purchaser pursuant to the Purchase Agreement for each 30-day period or pro rata portion thereof following the Effectiveness Deadline for which no Registration Statement has been
declared effective by the SEC. Notwithstanding anything to the contrary contained herein, in no event shall the aggregate liquidated damages payable by the Company to all Purchasers under this Agreement, including this Section 2(b), exceed ten
percent (10%) of the Purchaser’s aggregate purchase price paid pursuant to the Purchase Agreement, less any amount paid pursuant to Section 4.2(b) of the Purchase Agreement. Such payments shall constitute the Purchasers’
exclusive monetary remedy for such events, but shall not affect the right of the Purchasers to seek injunctive relief. Such payments shall be made to each Purchaser in cash no later than five (5) Business Days after the end of each 30-day
period. If the Company fails to pay any liquidated damages payments hereunder within five (5) Business Days of the date payable, the Company shall pay interest thereon at a rate of 18% per annum (or such lesser maximum amount that is
permitted to be paid by applicable law) to the Purchaser, accruing daily from the date the liquidated damages were initially due until such amounts are paid in full. 
 (c) Expenses. Except as provided for in this Agreement, all fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by the Company whether
or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, all of the Company’s expenses associated with each registration,
including registration filing fees, accounting and printing (if any) fees, and fees and disbursements of counsel for the Company. In no event shall the Company be responsible for any broker or similar discounts or commissions, or fees of
underwriters, selling brokers, dealer managers or similar securities industry professionals, with respect to the Registrable Securities being sold. 

  
 3 

 (d) Additional Registration Statements. If at any time the SEC
takes the position that the offering of some or all of the Registrable Securities in a Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 or requires any Purchaser in connection
with a Registration Statement filed under Section 2(a) to be named as an “underwriter,” the Company shall use its commercially reasonable efforts to persuade the SEC that the offering contemplated by the Registration Statement is a
valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that such Purchaser is not an “underwriter.” The Purchasers shall have the right to participate or have their counsel
participate in any meetings or discussions with the SEC regarding the SEC’s position and to comment or have their counsel comment on any written submission made to the SEC with respect thereto. No such written submission shall be made to the
SEC to which the Purchasers’ counsel reasonably objects, which determination shall be made in the sole discretion of the Company and its counsel. In the event that, despite the Company’s commercially reasonable efforts and compliance with
the terms of this Section 2(c), the SEC refuses to alter its position, the Company shall remove from the Registration Statement such portion of the Registrable Securities (the “Cut Back Shares”) and/or agree to such
restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company’s compliance with the requirements of Rule 415; provided, however, that the Company shall
not agree to name any Purchaser as an “underwriter” in such Registration Statement without the prior written consent of such Purchaser (collectively, the “SEC Restrictions”). Any cut-back imposed on the Purchasers
pursuant to this Section 2(c) shall be allocated among the Purchasers on a pro rata basis and shall be applied first to any of the Registrable Securities of such Purchaser as such Purchaser shall designate, unless the SEC Restrictions otherwise
require or provide or the Purchasers otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions
(such date, the “Restriction Termination Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section 2 (including the liquidated
damages provisions) shall again be applicable to such Cut Back Shares; provided, however, that (i) the Filing Deadline for the Registration Statement including such Cut Back Shares shall be ten (10) Business Days after such Restriction
Termination Date, and (ii) the date by which the Company is required to obtain effectiveness with respect to such Cut Back Shares under Section 2(d) shall be the 120th day immediately after the Restriction Termination Date. 

(e) Effectiveness. 
 (i) The Company shall use commercially reasonable efforts to cause each Registration Statement to be declared effective by the SEC as soon as practicable (including filing with the SEC a request for
acceleration of its effectiveness in accordance with Rule 461 within five (5) Business Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the staff of the SEC following the filing of the Updating
Amendment that such Registration Statement will not be reviewed, or not be subject to further review), with respect to the initial Registration Statement filed pursuant to Section 2(a) hereof, but in any event no later than June 1, 2011
(or, in the event of a “full review” by the Commission, one hundred and twenty (120) days after the Updating Deadline) (the “Effectiveness Deadline”), and in the case of any subsequent Registration Statement no later
than one hundred and twenty (120) days 

  
 4 

 
after filing of such Registration Statement. The Company shall notify the Purchasers by facsimile or e-mail as promptly as practicable, and in any event, within twenty-four (24) hours, after
any Registration Statement is declared effective and shall simultaneously provide the Purchasers with copies of any related Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Purchasers
hereby acknowledge and agree that, notwithstanding anything to the contrary contained herein, the Company shall have no obligation to use commercially reasonable efforts to cause the initial Registration Statement filed pursuant to Section 2(a)
hereof to be declared effective until such time as the Registration Statement has been amended on or before the Updating Deadline by the Updating Amendment pursuant to Section 2(a). 

(ii) The Purchasers hereby acknowledge that there may be times when the Company must suspend the use of a Prospectus until such time as
an amendment to the related Registration Statement has been filed by the Company and declared effective by the SEC or until the Company has amended or supplemented such Prospectus. Each Purchaser hereby covenants that it will not sell any securities
pursuant to any Prospectus during the period commencing at the time at which the Company gives the Purchasers notice of the suspension of the use of such Prospectus and ending at the time the Company gives the Purchasers notice that the Purchasers
may thereafter effect sales pursuant to such Prospectus. Notwithstanding anything herein to the contrary, the Company shall not suspend use of any Registration Statement by the Purchasers unless in the good faith determination of the Company such
suspension is necessary to (A) delay the disclosure of material non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or
(B) amend or supplement the affected Registration Statement or the related Prospectus as required by the federal securities laws or so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances under which they were made, not misleading (an “Allowed Delay”);
provided, however, that (X) except as otherwise provided by clause (Y) below, in the event that such suspension is required by the need for an amendment or supplement to a Registration Statement or a related Prospectus, the
Company shall promptly file such required amendments or supplements as shall be necessary for the disposition of the Registrable Securities to recommence and (Y) if the board of directors of the Company has determined in good faith that offers
and sales pursuant to a Prospectus should not be made by reason of the presence of material undisclosed circumstances or developments with respect to which the disclosure that would be required in the related Registration Statement would be
premature or would have a material adverse effect on the Company and its business, the Company may suspend the use of such Prospectus and defer the filing of any required amendment or supplement for the minimum period of time necessary to avoid such
material adverse effect. 
 3. Company Obligations. The Company will use all reasonable efforts to effect the
registration of the Registrable Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible (but subject to Sections 2(d) and 2(e)(ii)): 

(a) use commercially reasonable efforts to cause each Registration Statement to remain continuously effective for a period that will
terminate upon the earlier of (i) the date on 

  
 5 

 
which all Registrable Securities covered by such Registration Statement as amended from time to time, have been sold; and (ii) the date on which all Registrable Securities covered by such
Registration Statement may be sold without volume limitations pursuant to Rule 144 (the “Effectiveness Period”) and advise the Purchasers in writing when the Effectiveness Period has expired; 

(b) prepare and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may
be necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933 Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;

 (c) use all reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and,
(ii) if such order is issued, obtain the withdrawal of any such order at the earliest possible moment; 
 (d) prior to any
resale of Registrable Securities, use all reasonable efforts to register or qualify or cooperate with the Purchasers and their counsel in connection with the registration or qualification of such Registrable Securities for offer and sale under
the securities or blue sky laws of such jurisdictions requested by the Purchasers and do any and all other commercially reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable Securities
covered by the Registration Statement; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to
qualify but for this Section 3(d), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 3(d) or (iii) file a general consent to service of process in any such
jurisdiction; 
 (e) use all reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be
listed on each securities exchange, interdealer quotation system or other market (including the OTC Bulletin Board) on which similar securities issued by the Company are then listed or traded; 

(f) promptly notify the Purchasers, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon the happening
of any event as a result of which, the Prospectus included in a Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the
statements therein not misleading in light of the circumstances then existing, and promptly prepare, file with the SEC and furnish to the Purchasers a supplement to or an amendment of such Prospectus as may be necessary so that such Prospectus shall
not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; 

(g) promptly notify each Purchaser (i) of any request by the SEC or any other Federal or state governmental authority during the
Effectiveness Period of any Registration Statement for amendments or supplements to such Registration Statement or related Prospectus 

  
 6 

 
or for additional information; (ii) of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of any Registration
Statement covering any or all of the Registrable Securities or the initiation of any proceedings for that purpose; (iii) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any proceeding for such purpose; and (iv) of the occurrence of any event or passage of time that makes the financial statements
included in any Registration Statement ineligible for inclusion therein; and 
 (h) cooperate with the Selling Agent with
respect to any filing required by the FINRA Corporate Financing Department pursuant to FINRA Rule 5110. 
 4. Obligations of
the Purchasers. 
 (a) Each Purchaser shall promptly furnish in writing to the Company such information regarding itself,
the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration of such Registrable Securities and shall execute such documents in
connection with such registration as the Company may reasonably request. At least ten (10) Business Days prior to the first anticipated filing date of any Registration Statement, the Company shall notify each Purchaser of the information the
Company requires from such Purchaser if such Purchaser elects to have any of the Registrable Securities included in the Registration Statement. A Purchaser shall provide such information to the Company, including, without limitation, the information
requested in the Selling Stockholder Questionnaire attached to this Agreement as Exhibit B, at least two (2) Business Days prior to the first anticipated filing date of such Registration Statement if such Purchaser elects to have any of
the Registrable Securities included in the Registration Statement, provided, however, that a Purchaser’s Registrable Securities shall be included in any subsequent amendment to the Registration Statement if such Purchaser provides such
information prior to the filing date of any amendment to the Registration Statement, including the Updating Amendment. 
 (b)
Each Purchaser, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any Registration Statement hereunder, unless such Purchaser
has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement. 
 (c) Each Purchaser agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to Section 2(e)(ii), or (ii) the happening of an
event pursuant to Sections 3(f) or 3(g) hereof, such Purchaser will immediately discontinue disposition of Registrable Securities pursuant to all Registration Statements covering such Registrable Securities, until such Purchaser is advised by
the Company that a supplemented or amended prospectus has been filed with the SEC and until any related post-effective amendment is declared effective and, if so directed by the Company, such Purchaser shall deliver to the Company or destroy (and
deliver to the Company a certificate of destruction) all copies in such Purchaser’s possession of the Prospectus covering the Registrable Securities current at the time of receipt of such notice. 

  
 7 

 5. Indemnification. 

(a) Indemnification by the Company. The Company will indemnify and hold harmless each Purchaser and its officers, directors,
members, partners, employees, attorneys and agents, successors and assigns, and each other person, if any, who controls such Purchaser within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to
which they may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of
any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof; (ii) the omission or alleged omission to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the Company of the Securities Act, Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under this Agreement and will reimburse such Purchaser, and each such officer, director or member and each such controlling person for any legal or other expenses reasonably incurred by them in
connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable for amounts paid in settlement of any such loss, claim, damage, liability or action if
such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, and the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of
or is based upon (i) an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Prospectus or any amendment or supplement thereto in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such Purchaser expressly for use therein; (ii) the failure of such Purchaser to comply with the covenants and agreements contained in Section 4 hereof respecting the sale of the
Shares; (iii) the inaccuracy of any representation or warranty made by such Purchaser herein; or (iv) the use by such Purchaser of an outdated or defective Prospectus after the Company has notified such Purchaser in writing that the
Prospectus is outdated or defective. 
 (b) Indemnification by the Purchasers. Each Purchaser agrees, severally but not
jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of the Securities Act) against any losses,
claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement of a material fact or any omission of a material fact required to be stated in any Registration Statement or Prospectus or preliminary
prospectus or amendment or supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by such
Purchaser to the Company specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto and will reimburse the Company, its directors, officers, employees, stockholders and each person who controls the
Company (within the meaning of the Securities Act) for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage or liability (or action in respect thereof). In no event shall
the liability of a Purchaser be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Purchaser in connection with any claim relating to this Section 5) received by such Purchaser upon the sale of the
Registrable Securities included in the Registration Statement giving rise to such indemnification obligation. 

  
 8 

 (c) Conduct of Indemnification Proceedings. Any person entitled to indemnification
hereunder shall (i) give prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory
to the indemnified party; provided, that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at
the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such
person or (c) in the reasonable judgment of any such person, based upon written legal opinion of its counsel satisfactory to the indemnifying party, a conflict of interest exists between such person and the indemnifying party with respect to
such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense
of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent
that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same
jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or
enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. 

(d) Contribution. If for any reason the indemnification provided for in the preceding paragraphs 5(a) and 5(b) is unavailable
to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or
liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation within the
meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of a Purchaser of Registrable Securities be greater
in amount than the dollar amount of the proceeds (net of all expenses paid by such Purchaser in connection with any claim relating to this Section 5 and the amount of any damages such Purchaser has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation. 

6. Miscellaneous. 
 (a) Amendments and Waivers. This Agreement may be amended, modified or waived only by a writing signed by the Company and the Required Purchasers.

  
 9 

 
Notwithstanding the foregoing, a waiver or consent with respect to a matter that relates execlusively to the rights of one Purchaser or some Purchaser’s in particular and that does not
directly or indirectly affect the rights of all other Purchasers may be given by such Purchaser or Purchasers of all of the Registrable Securities to which such waiver or consent relates; provided, however, that the provisions of this sentence may
not be amended, modified or waived except in accordance with the provisions of the first sentence of this Section 6(a). 

(b) Notices. All notices and other communications provided for or permitted hereunder shall be made as set forth in
Section 5.4 of the Purchase Agreement. 
 (c) Assignments and Transfers by Purchasers. The provisions of this
Agreement shall be binding upon and inure to the benefit of the Purchasers and their respective successors and assigns. A Purchaser may transfer or assign, in whole or from time to time in part, to one or more persons its rights hereunder in
connection with the transfer of Registrable Securities by such Purchaser to such person; provided, that (i) such Purchaser complies with all laws applicable thereto and provides written notice of assignment to the Company promptly after
such assignment is effected and (ii) the transferee agrees in writing to be bound by this Agreement as if it were a party hereto. 
 (d) Assignments and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise) without the prior written consent of the Required
Purchasers; provided, however, that the Company may assign its rights and delegate its duties hereunder to any surviving or successor corporation in connection with a merger or consolidation of the Company with another corporation, or
a sale, transfer or other disposition of all or substantially all of the Company’s assets to another corporation, without the prior written consent of the Required Purchasers, after notice duly given by the Company to each Purchaser.

 (e) Benefits of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding
upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 (f)
Counterparts; Electronic Execution. This Agreement may be signed in one or more counterparts, each of which shall be deemed an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Signatures to
this Agreement transmitted by facsimile transmission, by electronic mail in PDF form, or by any other electronic means designed to preserve the original graphic and pictorial appearance of a document, will be deemed to have the same effect as
physical delivery of the paper document bearing the original signatures. 
 (g) Titles and Subtitles. The titles and
subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

  
 10 

 (h) Severability. Any provision of this Agreement that is prohibited or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to
the maximum extent permitted by applicable law so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party, and any such prohibition or unenforceability in any
jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. To the extent permitted by applicable law, the parties hereby waive any
provision of law which renders any provisions hereof prohibited or unenforceable in any respect. 
 (i) Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the
agreements herein contained. 
 (j) Entire Agreement. This Agreement is intended by the parties as a final expression of
their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein. This Agreement supersedes all prior agreements and understandings
between the parties with respect to such subject matter. 
 (k) Governing Law; Consent to Jurisdiction; Waiver of Jury
Trial. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof, except to the extent that the application of the General Corporation Law of the State of Delaware is mandatorily applicable. Each party agrees that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, employees or agents) shall be commenced exclusively in the state and
federal courts of the State of New York located in New York County and the United States District Court for the Southern District of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
located in New York County, New York, USA, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding has been commenced in an improper or inconvenient venue for such proceeding. Each party hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at
the address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to

  
 11 

 
serve process in any manner permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY. 
 [Signature pages
follow] 

  
 12 

 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first written above. 
  

			
	CAMBRIDGE HEART, INC.
		
	By:	 	   /s/ Ali Haghighi-Mood

		 	Name: Ali Haghighi-Mood
		 	Title: President and Chief Executive Officer

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK 
 SIGNATURE PAGE FOR PURCHASERS FOLLOW] 

 [PURCHASER SIGNATURE PAGES TO CAMBRIDGE HEART 

REGISTRATION RIGHTS AGREEMENT] 
  

			
	Name of Purchaser:	  	  

		
	Signature of Authorized Signatory:	  	  

		
	Name of Authorized Signatory:	  	  

		
	Title of Authorized Signatory:	  	  

 [SIGNATURE PAGES CONTINUE] 

 EXHIBIT A 
 PLAN OF DISTRIBUTION 
 The shares of common stock offered by this
prospectus are being offered by selling stockholders and their donees, pledgees, transferees or other successors-in-interest. The common stock may be sold, transferred or otherwise disposed of on any stock exchange, the OTC Bulletin Board or any
other market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying
prices determined at the time of sale, or at negotiated prices. 
 The selling stockholders may use any one or more of the
following methods when disposing of shares or interests therein: 
  

	 	•	 	 ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

 

	 	•	 	 block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to
facilitate the transaction; 

  

	 	•	 	 through brokers, dealers or underwriters who may act solely as agents; 

 

	 	•	 	 purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

 

	 	•	 	 an exchange distribution in accordance with the rules of the applicable exchange; 

 

	 	•	 	 privately negotiated transactions; 

  

	 	•	 	 short sales effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

  

	 	•	 	 through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

  

	 	•	 	 broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; or

  

	 	•	 	 a combination of any such methods of sale. 

 The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured
obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment or supplement to this prospectus under Rule 424(b)(3) or other applicable provision of
the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 

  
 A-1

 In connection with the sale of our common stock or interests therein, the selling
stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also
sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus,
which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 
 The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the
selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds
from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants. 
 The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act of 1933, provided that they meet the criteria
and conform to the requirements of that rule. 
 Each of the other selling stockholders and any underwriters, broker-dealers or
agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of
the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery
requirements of the Securities Act. 
 To the extent required, the shares of our common stock to be sold, the names of the
selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying
prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. 
 In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some
states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. 

  
 A-2

 Under applicable rules and regulations under the Exchange Act, any person engaged in the
distribution of the securities offered under this prospectus may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement
of the distribution. In addition, the selling stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of
shares of the common stock by the selling stockholders or any other person. We intend to make copies of this prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser
at or prior to the time of the sale. 
 We have agreed to indemnify the selling stockholders against liabilities, including
liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. 
 We have agreed to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered by this prospectus have been
disposed of or (2) the date on which all of the shares may be sold without volume limitations pursuant to Rule 144 of the Securities Act. We also are required to pay certain fees and expenses incurred by us incidential to the registration
of the shares of common stock. 

  
 A-3

 EXHIBIT B 
 CAMBRIDGE HEART, INC. 
 SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE

 The undersigned beneficial owner of common stock, par value $0.001 per share (the “Common Stock”), of
Cambridge Heart, Inc., a Delaware corporation (the “Company”), (the “Registrable Securities”) understands that the Company intends to file with the Securities and Exchange Commission (the
“Commission”) a registration statements on Form S-1 (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”), of
the Registrable Securities, in accordance with the terms of that certain Registration Rights Agreement, dated as of December 20, 2010 (the “Registration Rights Agreements”), among the Company and the Purchasers named therein. A
copy of the Registration Rights Agreement is available to any Purchaser thereunder upon request of the Company at the address set forth below. All capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in
the Registration Rights Agreement. 
 Certain legal consequences arise from being named as a selling stockholder in the
Registration Statements and any related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a
selling stockholder in the Registration Statements and any related prospectus. 
 NOTICE 

The undersigned beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the
Registrable Securities owned by it and listed below in Item 4 (unless otherwise specified under such Item 4) in the Registration Statement. The undersigned hereby provides the following information to the Company and represents and
warrants that such information is accurate: 
 QUESTIONNAIRE 

 

					
	        1.	  	Name:	  	
			
		  	(a)	  	Full Legal Name of Selling Stockholder
			
		  		  	  

			
		  	(b)	  	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
			
		  		  	  

  
 B-1

					
			
		  	(c)	  	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by
this Questionnaire):
			
		  		  	  

		
	        2.	  	Address for Notices to Selling Stockholder:
	
	  

	
	  

	
	  

			
	Telephone:	  	  

		
	Fax:	  	  

		
	Contact Person:	  	  

 

					
		
	        3.	  	Broker-Dealer Status:
			
		  	(a)	  	Are you a broker-dealer?
			
		  		  	
Yes     ̈               
     No     ̈

			
		  	(b)	  	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?
			
		  		  	
Yes     ̈               
     No     ̈

			
		  	Note:	  	If you answered “no” to Section 3(b), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration
Statement.
			
		  	(c)	  	Are you an affiliate of a broker-dealer?
			
		  		  	
Yes     ̈               
     No     ̈

  
 B-2

					
			
		  	(d)	  	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the
Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
			
		  		  	
Yes     ̈               
     No     ̈

			
		  	Note:	  	If you answered “no” to Section 3(d), the Commission’s staff has indicated that you should be identified as an underwriter in the Registration
Statement.
		
	4.	  	Beneficial Ownership of Registrable Securities:
			
		  	(a)	  	Type and Amount of Registrable Securities beneficially owned by the Selling Stockholder:
			
		  		  	  

			
		  		  	  

		
	5.	  	Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.
	
	Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than the Registrable
Securities listed above in Item 4.
			
		  	(a)	  	Type and Amount of other securities beneficially owned by the Selling Stockholder:
			
		  		  	  

			
		  		  	  

		
	6.	  	Relationships with the Company:
	
	Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity
securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.
		
		  	State any exceptions here:
		
		  	  

		
		  	  

  
 B-3

 The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the
information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective. 
 By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 6 and the inclusion of such information in the Registration Statement and
the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related
prospectus and any amendments or supplements thereto. 
 IN WITNESS WHEREOF the undersigned, by authority duly given, has caused
this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent. 
  

							
		 		 	Beneficial Owner:
				
	  
	 		 	By:	 	  

	Date	 		 		 	
		 		 	Name:	 	  

				
		 		 	Title:	 	  

 PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE, AND RETURN THE ORIGINAL BY OVERNIGHT MAIL, TO: 

Cambridge Heart, Inc. 
 Attn: Vincenzo LiCausi 
 100 Ames Pond Drive 

Tewksbury, MA 01876 

Email: vincenzol@cambridgeheart.com 
 Fax: (978) 654-4501 

  
 B-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]